Publication Name	World Journal of Gastroenterology
Manuscript ID	47845
Country	Israel

Received	2019-03-27 02:18
Peer-Review Started	2019-03-28 03:58
To Make the First Decision	2019-04-17 00:17
Return for Revision	2019-04-17 03:10
Revised	2019-05-29 19:07
Second Decision	2019-06-25 10:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-07-03 01:12
Articles in Press	2019-07-03 01:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-08-05 08:36
Publish the Manuscript Online	2019-08-07 07:09

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Manuscript Source	Invited Manuscript
All Author List	Hadar Meringer, Oren Shibolet and Liat Deutsch
ORCID	Author(s) ORCID Number Hadar Meringer http://orcid.org/0000-0002-2624-2505 Oren Shibolet http://orcid.org/0000-0003-6111-5067 Liat Deutsch http://orcid.org/0000-0001-5022-4318
Funding Agency and Grant Number
Corresponding Author	Liat Deutsch, MD, Doctor, Department of Gastroenterology and Hepatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, 6 Weizmann St., Tel-Aviv 64239, Israel. liatml@tlvmc.gov.il
Key Words	Hepatocellular carcinoma; Hepatitis C virus; Direct-acting antivirals; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis;
Core Tip	Hepatocellular carcinoma (HCC) is a common and deadly malignancy. One of the leading risk factors for HCC occurrence is liver cirrhosis secondary to hepatitis C virus (HCV) infection. Direct-acting antiviral therapy has revolutionized HCV eradication due to high sustained virologic response rates. However, early reports argued an increased risk of HCC occurrence and recurrence. Recently, non-alcoholic fatty liver disease has become the most common liver disorder in Western countries and a major cause of HCC. We aimed to review the changes in HCC management in the face of the changing epidemiology in the post-HCV era.
Publish Date	2019-08-07 07:09
Citation	Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019;25(29): 3929-3940
URL	https://www.wjgnet.com/1007-9327/full/v25/i29/3929.htm
DOI	https://dx.doi.org/10.3748/wjg.v25.i29.3929

Full Article (PDF)	WJG-25-3929.pdf
Full Article (Word)	WJG-25-3929.docx
Manuscript File	47845-Review.docx
Answering Reviewers	47845-Answering reviewers.pdf
Audio Core Tip	47845-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	47845-Conflict-of-interest statement.pdf
Copyright License Agreement	47845-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	47845-Language certificate.pdf
Peer-review Report	47845-Peer-review(s).pdf
Scientific Misconduct Check	47845-Scientific misconduct check.pdf
Scientific Editor Work List	47845-Scientific editor work list.pdf